Skip to main content
SpringerLink
Log in

Update 2016

Das können Sie heute für CED-Patienten tun

Current strategies in diagnosis and treatment of IBD

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die Einführung neuer Substanzen hat die therapeutischen Optionen bei Colitis ulcerosa und Morbus Crohn deutlich erweitert. Hier sind vor allem neue anti-TNF-Antikörper, aber auch Antiadhäsionsmoleküle mit einem innovativen Wirkmechanismus zu nennen. Hinzu kommt ein Paradigmenwechsel in der Behandlungsstrategie hin zu einer mehr personalisierten Medizin, wobei objektive Zielkriterien wie die Abheilung der Mukosa bzw. die transmurale Heilung als Orientierung gelten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Dong J, Wang H, Zhao J, Zhu W, Zhang L, Gong J et al. Ultrasound as a diagnostic tool in detecting active Crohn’s disease: a meta-analysis of prospective studies. European radiology. 2014;24(1):26–33. Epub 2013/08/08

    Article  PubMed  Google Scholar 

  2. Kucharzik T, Petersen F, Maaser C. Bowel Ultrasonography in Inflammatory Bowel Disease. Dig Dis. 2015;33 Suppl 1:17–25. Epub 2015/09/15

    Article  PubMed  Google Scholar 

  3. Panes J, Bouzas R, Chaparro M, Garcia-Sanchez V, Gisbert JP, Martinez de Guerenu B et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Alimentary pharmacology & therapeutics. 2011;34(2):125–45. Epub 2011/05/28

    Article  CAS  Google Scholar 

  4. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J et al. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn’s & colitis. 2013;7(12):982–1018. Epub 2013/11/05

    Article  Google Scholar 

  5. Calabrese E, Maaser C, Zorzi F, Kannengiesser K, Hanauer SB, Bruining DH et al. Bowel Ultrasonography in the Management of Crohn’s Disease. A Review with Recommendations of an International Panel of Experts. Inflammatory bowel diseases. 2016;22(5):1168–83. Epub 2016/03/10

    Article  PubMed  Google Scholar 

  6. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9 e3. Epub 2015/03/01

    Article  CAS  PubMed  Google Scholar 

  7. Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2015;13(3):522–30 e2. Epub 2014/07/30

    Article  CAS  Google Scholar 

  8. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–201. Epub 2011/07/05

    Article  CAS  PubMed  Google Scholar 

  9. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463–8; quiz e10–1. Epub 2009/10/13

    Article  PubMed  Google Scholar 

  10. Preiss JC, Bokemeyer B, Buhr HJ, Dignass A, Hauser W, Hartmann F et al. [Updated German clinical practice guideline on „Diagnosis and treatment of Crohn’s disease“ 2014]. Zeitschrift fur Gastroenterologie. 2014;52(12):1431–84. Epub 2014/12/05. Aktualisierte S3-Leitlinie“Diagnostik und Therapie des Morbus Crohn“ 2014

    Article  CAS  PubMed  Google Scholar 

  11. Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Zeitschrift fur Gastroenterologie. 2011;49(9):1276–341. Epub 2011/08/26

    Article  CAS  PubMed  Google Scholar 

  12. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D’Haens G, Gibson PR et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63(3):433–41. Epub 2013/02/26

    Article  CAS  PubMed  Google Scholar 

  13. Panes J, Lopez-Sanroman A, Bermejo F, Garcia-Sanchez V, Esteve M, Torres Y et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145(4):766–74 e1. Epub 2013/06/19

    Article  CAS  PubMed  Google Scholar 

  14. Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145(4):758–65 e2; quiz e14–5. Epub 2013/05/07

    Article  CAS  PubMed  Google Scholar 

  15. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25. Epub 2009/10/20

    Article  CAS  PubMed  Google Scholar 

  16. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390–9 e1. Epub 2012/05/16

    Article  PubMed  PubMed Central  Google Scholar 

  17. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. The New England journal of medicine. 2010;362(15):1383–95. Epub 2010/04/16

    Article  CAS  PubMed  Google Scholar 

  18. Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400 e3. Epub 2014/02/12

    Article  CAS  PubMed  Google Scholar 

  19. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–8 e1. Epub 2013/11/26

    Article  CAS  PubMed  Google Scholar 

  20. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70 e5; quiz e31. Epub 2011/09/29

    Article  CAS  PubMed  Google Scholar 

  21. Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. Gastroenterology. 2015;149(2):350–5 e2. Epub 2015/04/29

    Article  CAS  PubMed  Google Scholar 

  22. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Alimentary pharmacology & therapeutics. 2011;33(9):987–95. Epub 2011/03/04

    Article  CAS  Google Scholar 

  23. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109 e1. Epub 2013/06/19

    Article  CAS  PubMed  Google Scholar 

  24. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annals of the rheumatic diseases. 2013;72(10):1605–12. Epub 2013/05/21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Annals of the rheumatic diseases. 2013;72(10):1613–20. Epub 2013/05/21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gecse KB, Lovasz BD, Farkas K, Banai J, Bene L, Gasztonyi B et al. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. Journal of Crohn’s & colitis. 2016;10(2):133–40. Epub 2015/12/15

    Article  Google Scholar 

  27. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. The New England journal of medicine. 2013;369(8):711–21. Epub 2013/08/24

    Article  CAS  PubMed  Google Scholar 

  28. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013;369(8):699–710. Epub 2013/08/24

    Article  CAS  PubMed  Google Scholar 

  29. De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A et al. Crohn’s disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406–17. Epub 2014/12/30

    Article  PubMed  Google Scholar 

  30. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386(10006):1825–34. Epub 2015/09/08

    Article  PubMed  Google Scholar 

  31. Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2014;12(8):1246–56 e6. Epub 2014/02/19

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Allgemeine Innere Medizin und Gastroenterologie, Klinikum Lüneburg, Bögelstraße 1, D-21339, Lüneburg, Deutschland

    Torsten Kucharzik

Authors
  1. Torsten Kucharzik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Torsten Kucharzik.

Additional information

This article is part of a supplement not sponsored by the industry.

INTERESSENKONFLIKT

Der Autor erklärt, dass er sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließ. Er legt folgende potenzielle Interessenkonflikte offen: Vortrags- und Beratungstätigkeit für Abbvie, Biogen, Hospira, Mundipharma, Falk, Janssen, MSD, Novartis, Takeda.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kucharzik, T. Das können Sie heute für CED-Patienten tun. MMW - Fortschritte der Medizin 158 (Suppl 3), 74–82 (2016). https://doi.org/10.1007/s15006-016-8234-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-016-8234-9

Keywords

Search

Navigation